<template>
    <div>
        <HomeBanner />
        <Navbar :page_title="$route.name"/>

        <div class="mh-75">
            <div class="container mt-5">
                <div class="row">
                    <div class="col-12">
                        <p class="h1 mb-4 text-center avenir-bold title text-uppercase">
                          Guidelines for Abstract Submission,<br>E-Poster and Free Paper
                        </p>
                        <div class="content ">
                          <p class="avenir-regular fs-4">
                            <br><span class="avenir-bold">Abstracts for the E-Poster Exhibit and Free Paper Presentation</span>
                            must be submitted online through the RCD website.
                          </p>
                          <ol class="fs-4 avenir-regular">
                            <li class="mb-4">
                              The primary/presenting author must complete their registration to the 25th Regional Conference of Dermatology 2022 to be able to submit
                              their abstracts online.
                            </li>
                            <li class="mb-4">
                              All conference delegates can submit abstracts of their original research work
                              (i.e. case reports, clinical trials) for the E-Poster Exhibit.
                            </li>
                            <li class="mb-4">
                              Dermatology residents-in-training of LADS member societies can submit abstracts for both the E-Poster Exhibit and the Free Paper Presentation.
                            </li>
                            <li class="mb-4">
                              The abstract/manuscript should not have been published in any medical journal prior to the RCD 2022.
                            </li>
                            <li class="mb-4">
                              Abstracts cannot be identical to any abstract that has previously been presented at a major international meeting prior to the RCD 2022. An update to a presented research is acceptable.
                            </li>
                            <li>Submission of an abstract indicates:</li>
                            <ul class="list-style-type-disc mb-4">
                              <li>that the presentation is based on scientific and/or clinical methods that are ethical and valid;</li>
                              <li>that the author(s) agree to comply with the abstract submission and presentation rules;</li>
                              <li>that all authors have contributed to, agree and approve the abstract and its entire contents; and</li>
                              <li>all co-authors consent to being listed as authors.</li>
                            </ul>
                            <li class="mb-4">
                              Research work involving humans or animals must have approval of their institutional ethic committee or review board.
                            </li>
                          <li class="mb-4">
                            Abstracts will be reviewed and scored by a team of reviewers. The evaluation and scoring of the abstract (acceptance as poster or as oral communication,
                            or rejection) will be made according to a number of criteria, including:
                          </li>
                            <ol type="a">
                              <li>Significance of the study and its content</li>
                              <span class="fst-italic">Is the content interesting, informative, novel or important?</span>
                              <li>Research validity</li>
                              <span class="fst-italic">Are the methods valid, results relevant, and the conclusions justified by the data?</span>
                              <li>Clarity of data presentation</li>
                              <span class="fst-italic">Are the data presented with clarity and with appropriate structure</span>
                            </ol>
                            <li class="mb-4">
                              The RCD Research Committee will make the final decision on the format of presentation (i.e. oral or poster). Results of the selection process will be sent via e-mail to the submitting author. The Committee's decision is final and cannot be appealed.
                            </li>
                            <li class="mb-4">
                              Instructions on the preparation of posters or oral presentations and information about presentations will be included with the notification of acceptance.
                            </li>
                          </ol>
                        </div>
                    </div>
                </div>
            </div>

            <div class="container mt-5">
                <div class="row">
                    <div class="col-12">
                        <p class="h1 mb-3 text-center avenir-bold title mb-5">
                            Abstract Submission
                        </p>
                        <div class="content ps-3">
                            <div>
                                <p class="avenir-bold fs-4 text-uppercase color-005B97 mb-4">
                                    Abstract Preparation
                                </p>
                                <ol class="fs-4 avenir-regular">
                                    <li class="mb-4">
                                        Abstracts must be written and presented in English. Check spelling and grammar carefully. Abstracts that are not written in comprehensible
                                        English will be rejected and/or returned to the author(s) for revision.
                                    </li>
                                    <li class="mb-4">
                                        The <span class="avenir-bold">title</span> should be as brief as possible but long enough to clearly indicate the nature of the study.
                                        It should not contain any abbreviations.  Only the first letter of the first word  and proper nouns should be capitalized.
                                        Commercial trade names for drugs, devices, products, and services may not be used in the title.
                                    </li>
                                    <li class="mb-4">
                                       Please limit the number of authors to not more than five (5).
                                    </li>
                                    <li class="mb-4">
                                        <p class="mb-5">
                                          The <span class="avenir-bold">body of the abstract</span> should not exceed 300 words, and must be structured with the following subheadings:
                                        </p>
                                      <div class="container">
                                        <div class="row">
                                          <div class="col-sm">
                                            <p><span class="avenir-bold">For clinical investigative studies:</span><br>
                                                Introduction:<br>Objectives:<br>Methods:<br>Results:<br>Conclusions:
                                            </p>
                                          </div>
                                          <div class="col-sm"><p><span class="avenir-bold">For case reports or case series:</span><br>
                                            Background:<br>Observations:<br>Key message:
                                            </p>
                                          </div>
                                        </div>
                                      </div>
                                        <ol type="a">
                                            <li>
                                                Each sub-heading must be in bold font, followed by a colon ( : ) , and should begin on a new line.
                                            </li>
                                            <li>
                                                Only common and standard abbreviations and units (international metric system is preferred) should be used.
                                            </li>
                                            <li>
                                                Use generic names of drugs and devices.  Use or mention of trade names or commercial brand names.  Pharmaceutical company names are prohibited.
                                            </li>
                                            <li>
                                                Use of references, tables, charts or images are allowed.
                                            </li>
                                        </ol>
                                    </li>
                                    <li class="mb-5">Provide 3-5 <span class="avenir-bold">keywords</span> at the end of the abstract.</li>
                                </ol>
                            </div>
                            <div>
                                <p class="avenir-bold fs-4 text-uppercase color-005B97 mb-5">
                                    Abstract Topics
                                </p>
                                <p class="fs-4 avenir-regular mb-5">
                                    All abstracts will be classified into categories (see below). Please indicate on the online form the appropriate
                                    topic classifications to which your abstract belongs. Only 1 category must be chosen. The RCD Research Committee and abstract review team
                                    reserves the right to change the category chosen by the authors, if they determine it is more applicable to the submitted abstract.
                                </p>
                            </div>
                            <div class="mb-5">
                              <table class="table table-small">
                                <thead>
                                  <tr>
                                    <th colspan="2" class="text-uppercase text-center bg-dark-blue text-white marg">Categories</th>
                                  </tr>
                                </thead>
                                    <tbody>
                                      <tr>
                                        <td>Acne, hidradenitis suppurativa, rosacea</td>
                                        <td>Epidemiology & health services administration</td>
                                      </tr>
                                      <tr>
                                        <td>Aesthetic/cosmetic dermatology</td>
                                        <td>Genetics and genodermatoses</td>
                                      </tr>
                                      <tr>
                                        <td>Aging</td>
                                        <td>Hair & nail disorders</td>
                                      </tr>
                                      <tr>
                                        <td>Autoimmune disorders and connective tissue diseases</td>
                                        <td>Immunodermatology & blistering disorders</td>
                                      </tr>
                                      <tr>
                                        <td>Basic science</td>
                                        <td>Infections</td>
                                      </tr>
                                      <tr>
                                        <td>Carcinomas</td>
                                        <td>Pediatric dermatology</td>
                                      </tr>
                                      <tr>
                                        <td>Contact Dermatitis:  Allergic & Irritant</td>
                                        <td>Internal medicine dermatology </td>
                                      </tr>
                                      <tr>
                                        <td>COVID 19-related dermatosis/vaccine reactions</td>
                                        <td>Papulosquamous disorders</td>
                                      </tr>
                                      <tr>
                                        <td>Dermatology in the elderly</td>
                                        <td>Pharmacology</td>
                                      </tr>
                                      <tr>
                                        <td>Dermatology in women and during pregnancy</td>
                                        <td>Photobiology, phototherapy & photosensitivity diseases</td>
                                      </tr>
                                      <tr>
                                        <td>Dermatopathology</td>
                                        <td>Pigmented disorders & pigmentary changes</td>
                                      </tr>
                                      <tr>
                                        <td>Dermatologic Surgery</td>
                                        <td>Psychodermatology and neurocutaneous diseases</td>
                                      </tr>
                                      <tr>
                                        <td>Diagnostic techniques/immunostaining</td>
                                        <td>Sexually transmitted infections</td>
                                      </tr>
                                      <tr>
                                        <td>Digital/electronic technology (ie dermoscopy, digital imaging technology)</td>
                                        <td>Surgery (laser, cosmetic, dermatologic)</td>
                                      </tr>

                                      <tr>
                                        <td>Telemedicine</td>
                                        <td>Diseases/ Disorders of the apocrine, eccrine and sweat glands</td>
                                      </tr>
                                      <tr>
                                        <td>Tumors</td>
                                        <td>Disorders of the subcutaneous tissue</td>
                                      </tr>
                                      <tr>
                                        <td>Vascular anomalies/disorders</td>
                                        <td>Eczemas</td>
                                      </tr>
                                      <tr>
                                        <td>Wound healing, keloids &amp; ulcers</td>
                                        <td>Education and community service</td>
                                      </tr>

                                </tbody>
                              </table>
                            </div>
                            <div>
                              <p class="avenir-bold fs-4 text-uppercase color-005B97 mb-5">
                                  Acceptance Notification
                              </p>
                              <p class="fs-4 avenir-regular mb-5">
                                Authors will be notified starting on August 20, 2022 as to the  status of their submissions. This will include the assignment of category
                                and presentation format (oral or poster). Detailed instructions regarding requirements and instructions for oral and poster presentations will also
                                be provided at that time.
                              </p>
                            </div>
                            <div class="mb-5">
                                <p class="avenir-bold fs-4 text-uppercase mb-5 color-005B97">
                                    LADS Research Grant
                                </p>
                                <ol class="fs-4 avenir-regular">
                                    <li class="mb-4">
                                      Dermatology residents from LADS countries are eligible to submit abstracts for the Free Paper Presentation.
                                      A panel of judges will review the abstracts based on a set of criteria.
                                    </li>
                                    <li class="mb-4">
                                      Two Dermatology residents from each of the LADS countries will be awarded the LADS Research Grant amounting to USD 300.
                                    </li>
                                    <li class="mb-4">
                                      The RCD Research Committee will inform the grant awardees on August 20, 2022, and will give them the guidelines for their oral presentation.
                                    </li>
                                </ol>
                            </div>
                          <div>
                            <p class="italic">For any questions or clarifications:</p>
                            <p>Camille Berenguer-Angeles, MD<br>Chair, RCD Research Committee<br>email: <a href="mailto:rcdresearchcommittee@gmail.com">rcdresearchcommittee@gmail.com</a></p>
                          </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</template>

<script>
export default {
	layout: "home",
	data() {
		return {
            page_title: "Scientific Program"
        }
	},
};
</script>

<style lang="scss" scoped>
.title {
    line-height: 50px;
}
.bg-dark-blue{
  background-color: #00008b;
}
.table td {
  border-left: 1px solid #000;
  border-right: 1px solid #000;
  border-top: none!important;
  width: 230px;
}
.remove {
  border: none !important;
}

@media screen and (max-width: 768px) {
  table{
    padding: 0 !important;
    margin-left: -10px;
    font-size: 14px;
    td{
      padding: 0.5rem !important;
    }
  }
}
</style>
